• Clario accelerates your clinical trial from initiation to implementation. LEARN MORE →

Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)

      Discover Clario's AI solutions, where innovation meets expertise. Since 2018, we have revolutionized clinical trial endpoint analyses with more than 30 AI-enabled solutions across 600+ active trials, enhancing data quality and patient privacy while expediting data collection processes.

      Go to page
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials

      All the precision endpoint technology and services your virtual or hybrid trial needs to deliver more certain outcomes.

      Go to page
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Articles eCOA vs. paper

eCOA vs. paper

Which should I use for my upcoming trial?

Valdo Arnera, M.D. – eCOA Scientific Advisor

We recently discussed the basics of eCOA and how it improves clinical trial data quality. For example, when compared to paper-based assessments, eCOA eliminates inconsistent data, increases patient compliance, is preferred by patients and recommended by regulatory agencies.1-4

In most cases, it is recommended to use eCOA; however, there are scenarios when paper may be considered. In this piece, we discuss occasions where the use of eCOA for capturing patient data is critical versus when it is recommended and how sponsors can reap the many benefits electronic data capture provides.

When is it critical to use eCOA?

Valdo Arnera headshot

“There are several scenarios when it is critical to capture your endpoint data electronically rather than on paper.”

Valdo Arnera, M.D. – eCOA Scientific Advisor

These include:

  • Questionnaires and/or daily diaries which are supporting primary endpoints: eCOA should be used when the success of your trial resides on the collection of patient diaries, as electronic assessments deliver significantly higher-quality data and more accurate results than paper data collection.
  • Questionnaires that don’t support primary endpoints but are unsupervised: Without the supervision of a healthcare professional, patients may procrastinate, inaccurately record, or forget to record entries in their questionnaire. Electronic assessments are designed to minimize or eliminate these problems through:
    • Alarms that are programmed to remind patients to complete their questionnaires appropriately
    • Software that prevents back and forward filling
    • Real-time reporting that automatically alerts sites when patient compliance is below a set threshold, allowing sites to intervene when necessary.
  • Monitoring for Suicidal Ideation and Behavior (SIB): Sites must know in real-time if a patient is experiencing suicidal thoughts. Electronic tools, such as the self-reported electronic Columbia Suicide Severity Rating Scale (eC-SSRS) or the interviewer-rated C-SSRS, can achieve this level of urgency. The patient-reported version of the C-SSRS provides increased patient honesty, reduces rater variability, and allows real-time suicide risk notification.
  • Integrating data from another source: If patients inaccurately record or forget to record meter values from other devices like glucometers, eCOA features such as automatic data transfer and reminders offer an added layer of support.
  • Complex ClinROs: Complex calculations and scoring are error-prone and can be eliminated with automatic calculations. An example here would be the Psoriasis Area Severity Index [PASI].
  • Rare disease studies: These cases often have few participants in the study. It’s therefore essential to minimize missing and incomplete data.

When is it recommended to use eCOA?

To reduce burden and receive consistent, high-quality data, we also recommend using eCOA in the following scenarios:

  • Oncology trials: Regulators recommend using eCOA in oncology trials5 and are now requesting additional information about drug efficacy beyond survival, such as quality of life (e.g., symptom relief).
  • Large-scale studies: Errors incurred when using paper can result in significant delays and costs due to data cleansing and processing. This is especially true when working across diverse populations and in multiple countries.

When can paper be considered?

Aside from the scenarios mentioned above, there may be a small number of instances where sponsors could consider using paper. In the following three scenarios, paper may be an appropriate option.

  • Studies with a very small patient population: The financial cost of incorporating eCOA may be greater than the burden of collecting data manually.
  • Long-duration studies with infrequent questionnaire collection: the cost of deploying eCOA may make paper a more appropriate option.
  • Phase 1 studies: For example, in a trial taking place on-site over a single day with a group of healthy volunteers, the likelihood of non-compliance using paper is low.

In summary, it is important to understand when it is critical to use electronic Clinical Outcome Assessments and the immense benefits eCOA brings with it over paper-based data capture. Our Clario Science team is on hand to offer advice on which method is most appropriate for your trial. Contact our team of experts or visit our Science page for further information.


References

1 Food and Drug Administration, FDA. 2009. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.
2 Food and Drug Administration, FDA. 2010. Guidance for Industry: Electronic Source Documentation in Clinical Investigations.
3 EMEA, 2005. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products.
4 EMA 2014, Reflection Paper on the use of patient reported outcome 5 (PRO) measures in oncology studies
5 Food and Drug Administration, FDA. 2018. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Guidance for Industry

To discuss using electronic data capture for your next study, contact our Science Team or visit our new Science page.

Speak to a Scientist
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

The New Liver Lexicon

NASH by any other name would still be fatty liver (but going forward call it SLD) 

Read
Article

Leveraging eC-SSRS for Suicide Risk Assessment

Discover how eC-SSRS is redefining suicide risk assessments with unprecedented accuracy and reliability in oncology trials and beyond

Read
Article

Knowledge is Power: 5 Important Questions You Should Ask Your Sales Rep

How to ensure your prospective provider meets the gold standard for operations and data collection in medical imaging, cardiac safety, and eCOA

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

Thanks for your form. Our team will be in touch very soon.

  • © 2023 Clario

    • Legal and Privacy Terms
    • Security Governance
    • Cookie Policy
    • Impressum

Please enter your business email before proceeding to xTalks to complete registration.

×

Please enter your business email so we can connect with you to provide a personalized review.

×